Skip to main content
MedPathMedPath Home
Clinical Trials/NCT00351130
NCT00351130
Completed
Phase 4

An 8 Week Extension to a Randomized, Double-blind, Parallel Group, Active-controlled, Multi-center, 14 Week Study to Evaluate the Effectiveness of a Valsartan Versus and Amlodipine Treatment Strategy in Achieving Blood Pressure Control in Patients With Stage 1 or Stage 2 Hypertension or Uncontrolled on Present Monotherapy

Novartis1 site in 1 country79 target enrollmentJune 2006
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsHypertension

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Hypertension
Sponsor
Novartis
Enrollment
79
Locations
1
Primary Endpoint
Percentage of patients who reach BP goal, systolic <140 mmHg and diastolic <90 mmHg, after 22 weeks
Status
Completed
Last Updated
9 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSitesSimilar Trials

Overview

Brief Summary

Essential hypertension is a widespread disease which affects one out of every three adults in the industrialized world. It contributes to cardiovascular disease development, a major and well established risk factor. A patient non compliant to drug therapy is recognized as one of the primary reasons for inadequate blood pressure control.

Registry
clinicaltrials.gov
Start Date
June 2006
End Date
March 2007
Last Updated
9 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Novartis
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Percentage of patients who reach BP goal, systolic <140 mmHg and diastolic <90 mmHg, after 22 weeks

Secondary Outcomes

  • Percentage of patients who reach BP goal, systolic <140 mmHg and diastolic <90 mmHg, after 14 and 22 weeks
  • Adverse events after 22 weeks

Study Sites (1)

Loading locations...

Similar Trials

Completed
Not Applicable
Comprehensive Approach to Hypertension Management in NepalHypertension
NCT05292469Norwegian University of Science and Technology1,252
Unknown
Phase 2
Investigating the Use of Genetics to Guide Pharmacologic Therapy for HypertensionHypertension
NCT02988245Geneticure, LLC1,000
Unknown
Phase 3
Randomized Controlled Trial of Renal Denervation for Resistant HypertensionHypertension
NCT02900729Shanghai WiseGain Medical Devices Co., Ltd.254
Completed
Not Applicable
A ED-based Intervention to Improve Antihypertensive AdherenceHypertensive EmergencyHypertensionBlood Pressure
NCT02672787Vanderbilt University220
Completed
Not Applicable
Prevalence of Hypertensive Disease in Patients Presenting for Elective Surgery in the Western Cape, South AfricaHypertensive Episode
NCT03157661University of Cape Town382